"212 of participants received hydroxychloroquine, 211 received placebo";
"With hydroxychloroquine, 4 hospitalizations and 1 nonhospitalized death occurred (n = 5 events). With placebo, 10 hospitalizations and 1 hospitalized death occurred (n = 10 events); of these hospitalizations, 2 were not COVID-19–related (nonstudy medicine overdose and syncope)."
"At day 14 of the trial, 24% (49 of 201) receiving hydroxychloroquine reported symptoms versus 30% (59 of 194) receiving placebo"
Consequently, his results actually showed a 60% reduction in hospitalisation and a 50% reduction in hospitalisation and/or death *(or 37.5% reduction if you exclude the 2 nonCOVID-19 hospitalisations) and a 20% reduction in symptions at day 14.
Boulware is one of the authors of this study. He has done another study which the data also showed a positive effect for hydroxychloroquine but the sample size was too small to be statistically significant. Instead of concluding further study is required to confirm his positive findings he tends to report, because his findings were statistically not significant because of his chosen small sample size, that he has not found a statistical significant benefit to imply he has found no benefit from the use of hydroxychloroquine.
Futermore, most medical personal recommending hydroxychloroquine also say it should also be taken in conjunction with azithromycin and zinc.
"After adjusting for the time at which zinc sulfate was added to our protocol, an increased frequency of being discharged home (OR 1.53, 95% CI 1.12-2.09) reduction in mortality or transfer to hospice remained significant (OR 0.449, 95% CI 0.271-0.744). "
